Irinotecan Medicus

Irinotecan Hydrochloride Trihydrate, the active ingredient in Irinotecan Medicus, is a Topoisomerase I inhibitor presented as a solution for injection for intravenous use. It treats metastatic colorectal cancer and other solid tumors in adult patients.

GNH USA supplies Irinotecan Medicus as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Irinotecan Medicus is employed in oncology protocols targeting DNA replication pathways in malignant disease.

Metastatic colorectal cancer: improves overall survival when used in combination chemotherapy regimens. Colorectal adenocarcinoma: provides tumor control in advanced disease stages. Other solid tumors: may be incorporated into approved treatment protocols for selected tumor types.

Irinotecan may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Diarrhea: often severe and may require antidiarrheal therapy. - Neutropenia: reduced white blood cell count increasing infection risk. - Nausea and vomiting: may be managed with antiemetics. - Alopecia: temporary hair loss during treatment. - Fatigue: generalized tiredness affecting daily activities. - Abdominal cramping: discomfort in the gastrointestinal tract.

Serious or Rare Side Effects: - Febrile neutropenia: fever with low neutrophil count requiring urgent care. - Severe colitis (including ileitis): inflammation of the colon that can be life‑threatening. - Hepatotoxicity: elevated liver enzymes indicating liver injury. - Hypersensitivity reactions: rash, bronchospasm, or anaphylaxis in rare cases.

Before initiating therapy, clinicians should assess patient suitability and monitor for known risks. - Baseline blood counts: obtain complete blood count to detect pre‑existing cytopenias. - Liver function: evaluate hepatic enzymes as irinotecan metabolism is hepatic. - UGT1A1 genotype: consider testing for reduced enzyme activity that may increase toxicity. - Concomitant myelosuppressive agents: adjust dosing or schedule to avoid excessive bone‑marrow suppression. - Pregnancy and lactation: avoid use due to unknown fetal risk; discontinue if pregnancy occurs. - Store at ambient temperature: keep in original container, protect from light and moisture, and do not freeze.

Irinotecan interacts with several drug classes that may alter its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase irinotecan exposure. - UGT1A1 inhibitors (e.g., atazanavir): can raise SN‑38 levels and toxicity. - Concurrent high‑dose irinotecan formulations: risk of cumulative toxicity.

Moderate Interactions (Monitor Closely): - Other myelosuppressive agents (e.g., carboplatin): monitor blood counts closely. - Anticoagulants (e.g., warfarin): increased bleeding risk with mucosal injury. - Antidiarrheal agents (e.g., loperamide): may mask early signs of severe diarrhea. - CYP3A4 inducers (e.g., rifampin): may reduce therapeutic effect. - Herbal supplements affecting liver enzymes (e.g., St. John’s wort): monitor for altered drug levels.